Cargando…

Analgesic characteristics of a newly developed α(2)δ ligand, mirogabalin, on inflammatory pain

Mirogabalin is a novel α(2)δ ligand approved in Japan for the treatment of peripheral neuropathic pain. However, the sites of action of α(2)δ ligands to produce analgesic effects on inflammatory pain remain unclear. In this study, we investigated the analgesic effect and site of action of mirogabali...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komatsu, Shuji, Nakamura, Shingo, Nonaka, Takahiro, Yamada, Toshihiko, Yamamoto, Tatsuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649095/ https://www.ncbi.nlm.nih.gov/pubmed/34823399 http://dx.doi.org/10.1177/17448069211052167

Ejemplares similares

Neuropeptide W, an endogenous NPBW1 and NPBW2 ligand, produced an analgesic effect via activation of the descending pain modulatory system during a rat formalin test
por: Nakamura, Shingo, et al.
Publicado: (2021)

Mirogabalin—A Novel Selective Ligand for the α2δ Calcium Channel Subunit
por: Zajączkowska, Renata, et al.
Publicado: (2021)

Oral morphine induces spinal 5‐hydroxytryptamine (5‐HT) release using an opioid receptor‐independent mechanism
por: Nakamura, Shingo, et al.
Publicado: (2023)

Frequency of Adverse Drug Reactions and Analgesic Effects of Mirogabalin during Treatment of Peripheral Neuropathic Pain: A Retrospective Clinical Investigation
por: Inage, Kazuhide, et al.
Publicado: (2020)

A Probable Case of Mirogabalin-Induced Neutropenia
por: Takahashi, Saeko, et al.
Publicado: (2020)

A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA
por: Nonaka, Takahiro, et al.
Publicado: (2017)

Mirogabalin and emerging therapies for diabetic neuropathy
por: Javed, Saad, et al.
Publicado: (2018)

Therapeutic Effect of Mirogabalin on Peripheral Neuropathic Pain due to Lumbar Spine Disease
por: Kim, Kyongsong, et al.
Publicado: (2021)

Mirogabalin, a selective gabapentinoid for managing neuropathic pain—A curtain raiser
por: Nair, Abhijit
Publicado: (2022)

The Clinical Application and Progress of Mirogabalin on Neuropathic Pain as a Novel Selective Gabapentinoids
por: Tang, Hui, et al.
Publicado: (2023)

Abuse potential of mirogabalin in recreational polydrug users
por: Mendell, Jeanne, et al.
Publicado: (2019)

Mirogabalin: could it be the next generation gabapentin or pregabalin?
por: Kim, Jae-Yeon, et al.
Publicado: (2021)

Analgesic Effect of the Newly Developed S(+)‐Flurbiprofen Plaster on Inflammatory Pain in a Rat Adjuvant‐Induced Arthritis Model
por: Sugimoto, Masanori, et al.
Publicado: (2016)

Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study
por: Tetsunaga, Tomoko, et al.
Publicado: (2020)

Long‐term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain
por: Baba, Masayuki, et al.
Publicado: (2019)

Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence
por: Chen, Eric Y., et al.
Publicado: (2021)

Effects of Mirogabalin on Hyperalgesia and Chronic Ocular Pain in Tear-Deficient Dry-Eye Rats
por: Kikuchi, Kasumi, et al.
Publicado: (2023)

Mirogabalin Decreases Pain-like Behaviours and Improves Opioid and Ketamine Antinociception in a Mouse Model of Neuropathic Pain
por: Zajączkowska, Renata, et al.
Publicado: (2022)

Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients
por: Sugimoto, Mitsuru, et al.
Publicado: (2021)

Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain
por: Yamamoto, Tatsuo, et al.
Publicado: (2008)

Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin
por: Yamanaka, Takuya, et al.
Publicado: (2022)

Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia
por: Ushida, Takahiro, et al.
Publicado: (2023)

Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia
por: Ushida, Takahiro, et al.
Publicado: (2023)

Switching From Pregabalin to Mirogabalin in Patients with Peripheral Neuropathic Pain: A Multi-Center, Prospective, Single-Arm, Open-Label Study (MIROP Study)
por: Kimura, Yoshiyuki, et al.
Publicado: (2021)

Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study
por: Nikaido, Takuya, et al.
Publicado: (2022)

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies
por: Brown, Karen, et al.
Publicado: (2018)

Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin: A Novel Case Report
por: Saito, Yoshitaka, et al.
Publicado: (2022)

Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study)
por: Misawa, Sonoko, et al.
Publicado: (2023)

Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled phase III study in Asian patients
por: Baba, Masayuki, et al.
Publicado: (2019)

Correction to: Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study
por: Nikaido, Takuya, et al.
Publicado: (2022)

Clinical Effectiveness of Mirogabalin Besylate for Trigeminal Neuropathy after Skull Base Surgery: Illustrative Cases
por: Karatsu, Kosuke, et al.
Publicado: (2023)

Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study
por: Baba, Masayuki, et al.
Publicado: (2020)

Somnolence and Dizziness During Mirogabalin Treatment in Patients With Neuropathic Pain Related to Lumbar Disease Who Switched From Pregabalin: A Retrospective Study
por: Akazawa, Tsutomu, et al.
Publicado: (2021)

Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment
por: Kato, Manabu, et al.
Publicado: (2017)

A Novel G Protein–Biased Agonist at the δ Opioid Receptor with Analgesic Efficacy in Models of Chronic Pain
por: Conibear, Alexandra E., et al.
Publicado: (2020)

Hydrogen Sulfide Increases the Analgesic Effects of µ- and δ-Opioid Receptors during Neuropathic Pain: Pathways Implicated
por: Bai, Xue, et al.
Publicado: (2022)

Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study protocol for a multicenter, randomized, open-label, parallel-group, interventional trial
por: Doi, Ryoichiro, et al.
Publicado: (2021)

Analgesic effects of calcitonin on radicular pain in male rats
por: Terashima, Yoshinori, et al.
Publicado: (2019)

Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain
por: Ferrari, Flora, et al.
Publicado: (2011)

Mirogabalin Decreases Pain-like Behaviors by Inhibiting the Microglial/Macrophage Activation, p38MAPK Signaling, and Pronociceptive CCL2 and CCL5 Release in a Mouse Model of Neuropathic Pain
por: Zajączkowska, Renata, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_htf69ebsvfo7ke9hs2cscb09dd